Evidence mapPaperPMID 38526804Full record

ArticleOphthalmology and therapy2024

Diabetic Disease of the Eye in Canada: Consensus Statements from a Retina Specialist Working Group.

Amer Omar, R Geoff Williams, James Whelan, Jason Noble, Michael H Brent, Michel Giunta, Sébastien Olivier, Mustapha Lhor

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Amer OmarMedical Retina Institute of Montreal, 2170 René-Lévesque Blvd Ouest, Bureau 101, Montréal, QC, H3H 2T8, Canada. amer.omar@medret.ca.ORCID http://orcid.org/0000-0003-1520-392X
R Geoff WilliamsCalgary Retina Consultants, University of Calgary, Calgary, AB, Canada.ORCID http://orcid.org/0000-0002-6747-3473
James WhelanFaculty of Medicine, Memorial University, St. John's, NF, Canada.
Jason NobleDepartment of Ophthalmology and Vision Science, University of Toronto, Toronto, ON, Canada.
Michael H BrentDepartment of Ophthalmology and Vision Science, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-8720-5185
Michel GiuntaDepartment of Ophthalmology, University of Sherbrooke, Sherbrooke, QC, Canada.
Sébastien OlivierCentre Universitaire d'ophtalmologie, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, QC, Canada.
Mustapha LhorMedical and Scientific Affairs Ophthalmology, Bayer Inc., Mississauga, ON, Canada.
University of Toronto · CABayer (Canada) · CAHôpital Maisonneuve-Rosemont · CAMemorial University of Newfoundland · CAMontreal Heart Institute · CAUniversité de Sherbrooke · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in systemic care, diabetic disease of the eye (DDE) remains the leading cause of blindness worldwide. There is a critical gap of up-to-date, evidence-based guidance for ophthalmologists in Canada that includes evidence from recent randomized controlled trials. Previous guidance has not always given special consideration to applying treatments and managing DDE in the context of the healthcare system. This consensus statement aims to assist practitioners in the field by providing a spectrum of acceptable opinions on DDE treatment and management from recognized experts in the field. In compiling evidence and generating consensus, a working group of retinal specialists in Canada addressed clinical questions surrounding the four themes of disease, patient, management, and collaboration. The working group reviewed literature representing the highest level of evidence on DDE and shared their opinions on topics surrounding the epidemiology and pathophysiology of diabetic retinopathy and diabetic macular edema; diagnosis and monitoring; considerations around diabetes medication use; strategic considerations for management given systemic comorbidities, ocular comorbidities, and pregnancy; treatment goals and modalities for diabetic macular edema, non-proliferative and proliferative diabetic retinopathy, and retinal detachment; and interdisciplinary collaboration. Ultimately, this work highlighted that the retinal examination in DDE not only informs the treating ophthalmologist but can serve as a global index for disease progression across many tissues of the body. It highlighted further that DDE can be treated regardless of diabetic control, that a systemic approach to patient care will result in the best health outcomes, and prevention of visual complications requires a multidisciplinary management approach. Ophthalmologists must tailor their clinical approach to the needs and circumstances of individual patients and work within the realities of their healthcare setting.

Indexed as

Diabetes complicationsDiabetic disease of the eyeDiabetic retinopathyMacular edemaTherapeutics

Identifiers

PMID38526804
PMCPMC11039592
OpenAlexW4393159685

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.